The renal protective effect of angiotensin receptor blockers depends on intra‐individual response variation in multiple risk markers

Abstract

Aims Angiotensin receptor blockers (ARBs) are renoprotective and targeted to blood pressure. However, ARBs have multiple other (off‐target) effects which may affect renal outcome. It is unknown whether on‐target and off‐target effects are congruent within individuals. If not, this variation in short term effects may have important implications for the prediction of individual long term renal outcomes. Our aim was to assess intra‐individual variability in multiple parameters in response to ARBs in type 2 diabetes. Methods Changes in systolic blood pressure (SBP), albuminuria, potassium, haemoglobin, cholesterol and uric acid after 6 months of losartan treatment were assessed in the RENAAL database. Improvement in predictive performance of renal outcomes (ESRD or doubling serum creatinine) for each individual using ARB‐induced changes in all risk markers was assessed by the relative integrative discrimination index (RIDI). Results SBP response showed high variability (mean –5.7 mmHg, 5th to 95th percentile –36.5 to +24.0 mmHg) between individuals. Changes in off‐target parameters also showed high variability between individuals. No congruency was observed between responses to losartan in multiple parameters within individuals. Using individual responses in all risk markers significantly improved renal risk prediction (RIDI 30.4%, P < 0.01) compared with using only SBP changes. Results were successfully replicated in two independent trials with irbesartan, IDNT and IRMA‐2. Conclusions In this post hoc analysis we showed that ARBs have multiple off‐target effects which vary between and within individuals. Combining all ARB‐induced responses beyond SBP provides a more accurate prediction of who will benefit from ARB therapy. Prospective trials are required to validate these findings.

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers

“…The finding that the albuminuria‐lowering effect of dapagliflozin was independent of changes in HbA1c or SBP suggests a dissociation of the albuminuria response from responses in HbA1c or SBP. This uncoupling of responses in multiple characteristics of a single drug has also been observed with other drugs including ACE inhibitors, ARBs, dipeptidyl peptidase‐4 inhibitors and endothelin receptor antagonists . The underlying mechanisms of this uncoupling in response are unknown and require further study.…”

Surrogate endpoints in clinical trials of chronic kidney disease progression

“…Interestingly, the ARBs significantly changed seven out of 11 measured renal risk markers. Integrating all risk markers in a score showed that it provided a better prediction of the drug effect on hard renal outcomes than any change in single markers [42,43]. External validation studies confirmed these results [44].…”

An integrative systems biology approach for precision medicine in diabetic kidney disease

“…Clinical trials in patients with DKD focus on response in the overall population but do not take into account how patients respond to the drug individually. Careful subgroup analyses of recent trials in DKD, albeit post‐hoc, suggested that disease molecular pathology differed between subgroups and disease subgroups associated with response, such that a subgroup of patients benefitted whereas other subgroups did not or were even harmed . The failure of almost all trials in the last decade indicates that this one‐size fits all approach is inadequate.…”